Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Treasury Shares (2017 - 2024)

Historic Treasury Shares for Coherus Oncology (CHRS) over the last 10 years, with Q4 2024 value amounting to $768237.0.

  • Coherus Oncology's Treasury Shares fell 5550.91% to $768237.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $768237.0, marking a year-over-year decrease of 5550.91%. This contributed to the annual value of $768237.0 for FY2024, which is 5550.91% down from last year.
  • Coherus Oncology's Treasury Shares amounted to $768237.0 in Q4 2024, which was down 5550.91% from $1.7 million recorded in Q4 2023.
  • In the past 5 years, Coherus Oncology's Treasury Shares registered a high of $2.3 million during Q4 2022, and its lowest value of $768237.0 during Q4 2024.
  • In the last 5 years, Coherus Oncology's Treasury Shares had a median value of $1.7 million in 2023 and averaged $1.5 million.
  • Per our database at Business Quant, Coherus Oncology's Treasury Shares skyrocketed by 86387.3% in 2020 and then tumbled by 5550.91% in 2024.
  • Coherus Oncology's Treasury Shares (Quarter) stood at $1.0 million in 2020, then skyrocketed by 82.61% to $1.8 million in 2021, then increased by 26.55% to $2.3 million in 2022, then fell by 26.0% to $1.7 million in 2023, then crashed by 55.51% to $768237.0 in 2024.
  • Its last three reported values are $768237.0 in Q4 2024, $1.7 million for Q4 2023, and $2.3 million during Q4 2022.